Healthcare · Medical Devices
LMAT LeMaitre Vascular
High convictionSmall capFYE December
Next print
FY26 Q1 · 2026-04-30
After-hours close
Consensus Rev
$62.5M
Street median
Consensus EPS
$0.52
Street median
Peer read-throughs
0
none flagged
Last print — FY25 Q4 (2026-02-25)
Revenue (Actual)
$60.3M
vs CE $58.9M (+2.4%)
EPS (Actual)
$0.48
vs CE $0.46 (+4.3%)
Stock reaction
+2.1%
Day-1 move vs Street
Headline call
Beat
vs CE framework
Thesis pillars
Edit thesis →- Pricing powerStrengthenedMid-single digit price realization sustains; GM 70%+.
- Rep productivityUnchangedDirect sales expansion into new geographies on plan.
Segments
- Vasculartracked
Historical Quick Looks
All history →| Date | Qtr | Mode | Headline | Reaction | |
|---|---|---|---|---|---|
| 2026-02-25 | FY25 Q4 | writeup | Earnings call: EU macro stable, no push-outs, rep adds ahead of plan | +2.1% | Open |
| 2026-02-25 | FY25 Q4 | quick | Price + mix drive GM to all-time high; guidance conservative | +2.1% | Open |
Context files
Upload →- No context files yet for LMAT.